Risk Factors Update Summary
- Added potential acquisitions of other companies and complex reimbursement process dependencies.
- Competitive bidding process changes under Medicare and consolidation in the healthcare industry.
- Sales revenue to top 10 customers decreased from 30.5% to 25.2% in 2022.
- Research and development expenses increased from $14.1 million in 2021 to $21.9 million in 2023.
- Medicare reimbursement rates for oxygen equipment decreased from $125.00 to $93.61 in 2024.
- International product sales revenue increased from $0.7 million in 2021 to $0.2 million in 2023.
- Turnover in senior executives and key technical personnel may impact business operations.
Full Text Changes in Most Recent 10-K
Intended use: review the highlighted statements. These are additions to the risk factors disclosure in the most recent 10-K filing compared to the previous 10-K filing. Deleted and moved text is less important and is shown for context.
To view the full company filings, click on the following link to be taken to the SEC EDGAR database landing page for the company: https://www.sec.gov/edgar/browse/?CIK=1294133&owner=exclude
This content requires a 'Free' membership to view. Please create one here.
This content requires a 'Free' membership to view. Please create one here.